For 34 indications (24.1%), a drug’s lack of a statistically significant OS benefit was documented before approval (except for osimertinib for second-line therapy in epidermal growth factor receptor T790M–positive advanced non–small cell lung cancer, for which OS data matured after approval). Here, EGFR is linked to lung cancer.